PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tirzepatide - Weight management in adults
PAD Profile : Tirzepatide - Weight management in adults
Keywords :
obesity, weight loss, overweight
Brand Names Include :
Mounjaro
Traffic Light Status
Status 1 of 1.
Status :
Non Formulary
Formulations :
- Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Tirzepatide should not be prescribed for the treatment of obesity until it has been approved for this indication at the Area Prescribing Committee. The Area Prescribing Committee will be considering a paper in March 2025, after this meeting this page will be updated with the outcome.
See the NHSE FAQ document below for further information.
Associated BNF Codes
06. Endocrine System
06.01.02. Antidiabetic drugs